Progress and challenges in the prevention and control of nonalcoholic fatty liver disease
Nonalcoholic fatty liver disease (NAFLD) is rapidly becoming the most common liver disease worldwide. Individuals with NAFLD have a high frequency of developing progressive liver disease and metabolism‐related comorbidities, which result from of a lack of awareness and poor surveillance of the disea...
Saved in:
| Published in | Medicinal research reviews Vol. 39; no. 1; pp. 328 - 348 |
|---|---|
| Main Authors | , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Wiley Subscription Services, Inc
01.01.2019
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Nonalcoholic fatty liver disease (NAFLD) is rapidly becoming the most common liver disease worldwide. Individuals with NAFLD have a high frequency of developing progressive liver disease and metabolism‐related comorbidities, which result from of a lack of awareness and poor surveillance of the disease and a paucity of approved and effective therapies. Managing the complications of NAFLD has already begun to place a tremendous burden on health‐care systems. Although efforts to identify effective therapies are underway, the lack of validated preclinical NAFLD models that represent the biology and outcomes of human disease remains a major barrier. This review summarizes the characteristics and prevalence of the disease and the status of our understanding of its mechanisms and potential therapeutic targets. |
|---|---|
| AbstractList | Nonalcoholic fatty liver disease (NAFLD) is rapidly becoming the most common liver disease worldwide. Individuals with NAFLD have a high frequency of developing progressive liver disease and metabolism‐related comorbidities, which result from of a lack of awareness and poor surveillance of the disease and a paucity of approved and effective therapies. Managing the complications of NAFLD has already begun to place a tremendous burden on health‐care systems. Although efforts to identify effective therapies are underway, the lack of validated preclinical NAFLD models that represent the biology and outcomes of human disease remains a major barrier. This review summarizes the characteristics and prevalence of the disease and the status of our understanding of its mechanisms and potential therapeutic targets. Nonalcoholic fatty liver disease (NAFLD) is rapidly becoming the most common liver disease worldwide. Individuals with NAFLD have a high frequency of developing progressive liver disease and metabolism-related comorbidities, which result from of a lack of awareness and poor surveillance of the disease and a paucity of approved and effective therapies. Managing the complications of NAFLD has already begun to place a tremendous burden on health-care systems. Although efforts to identify effective therapies are underway, the lack of validated preclinical NAFLD models that represent the biology and outcomes of human disease remains a major barrier. This review summarizes the characteristics and prevalence of the disease and the status of our understanding of its mechanisms and potential therapeutic targets.Nonalcoholic fatty liver disease (NAFLD) is rapidly becoming the most common liver disease worldwide. Individuals with NAFLD have a high frequency of developing progressive liver disease and metabolism-related comorbidities, which result from of a lack of awareness and poor surveillance of the disease and a paucity of approved and effective therapies. Managing the complications of NAFLD has already begun to place a tremendous burden on health-care systems. Although efforts to identify effective therapies are underway, the lack of validated preclinical NAFLD models that represent the biology and outcomes of human disease remains a major barrier. This review summarizes the characteristics and prevalence of the disease and the status of our understanding of its mechanisms and potential therapeutic targets. Nonalcoholic fatty liver disease (NAFLD) is rapidly becoming the most common liver disease worldwide. Individuals with NAFLD have a high frequency of developing progressive liver disease and metabolism‐related comorbidities, which result from of a lack of awareness and poor surveillance of the disease and a paucity of approved and effective therapies. Managing the complications of NAFLD has already begun to place a tremendous burden on health‐care systems. Although efforts to identify effective therapies are underway, the lack of validated preclinical NAFLD models that represent the biology and outcomes of human disease remains a major barrier. This review summarizes the characteristics and prevalence of the disease and the status of our understanding of its mechanisms and potential therapeutic targets. |
| Author | Li, Hongliang Zhang, Xiao‐Jing Cai, Jingjing |
| Author_xml | – sequence: 1 givenname: Jingjing orcidid: 0000-0003-2466-754X surname: Cai fullname: Cai, Jingjing organization: Institute of Model Animal of Wuhan University – sequence: 2 givenname: Xiao‐Jing surname: Zhang fullname: Zhang, Xiao‐Jing organization: Institute of Model Animal of Wuhan University – sequence: 3 givenname: Hongliang surname: Li fullname: Li, Hongliang email: lihl@whu.edu.cn organization: Wuhan University |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29846945$$D View this record in MEDLINE/PubMed |
| BookMark | eNp10U1vEzEQBmALFdG0cOAPIEtc4JDW44_17hGV8iG1Kgc4cLIce7Zx5djB3rTKv69D0ksFJ1vW8448MyfkKOWEhLwFdgaM8fMV-jMOCtQLMgM29HMA3h-RGYN27wRXx-Sk1jvGoCHxihzzoZfdINWM_P5R8m3BWqlNnrqljRHTLVYaEp2WSNcF7zFNIac9yGkqOdI80vYHG11e5hgcHe00bWkM91ioDxVtxdfk5WhjxTeH85T8-nL58-Lb_Orm6_eLT1dzJ5RQ83HosfcSPMIwDp1moBxz0HXDwsJCCGmR98As80LqUWPXC9_eNeuY115YcUo-7OuuS_6zwTqZVagOY7QJ86YazqTmSiupG33_jN7lTWltNAWy11LIgTf17qA2izZZsy5hZcvWPA2tgfM9cCXXWnA0Lkx2N6Op2BANMLNbi9mF_66lJT4-SzwV_Zc9VH8IEbf_h-b68vM-8Qhv_5qQ |
| CitedBy_id | crossref_primary_10_1161_CIRCRESAHA_121_319059 crossref_primary_10_1186_s12920_022_01300_1 crossref_primary_10_3389_fendo_2023_1173826 crossref_primary_10_1097_MD_0000000000034437 crossref_primary_10_1002_hep_31150 crossref_primary_10_1038_s41598_018_35653_4 crossref_primary_10_1016_j_ejphar_2022_174988 crossref_primary_10_7759_cureus_45884 crossref_primary_10_1038_s41598_024_69053_8 crossref_primary_10_1016_j_jhepr_2023_100962 crossref_primary_10_1016_j_tem_2019_08_006 crossref_primary_10_3389_fmed_2021_761538 crossref_primary_10_1016_j_freeradbiomed_2020_02_025 crossref_primary_10_1016_j_tem_2018_08_003 crossref_primary_10_1360_SSV_2024_0098 crossref_primary_10_1016_j_bbrc_2024_150003 crossref_primary_10_31146_1682_8658_ecg_218_10_175_181 crossref_primary_10_3389_fnut_2024_1494497 crossref_primary_10_1002_hep_30506 crossref_primary_10_1007_s10620_023_08212_9 crossref_primary_10_4103_sjg_sjg_484_22 crossref_primary_10_1038_s41467_024_53002_0 crossref_primary_10_3389_fphar_2020_00483 crossref_primary_10_1080_00365521_2022_2148835 crossref_primary_10_1002_hep_32126 crossref_primary_10_1002_ptr_7605 crossref_primary_10_1038_s42003_023_04613_8 crossref_primary_10_1136_bmjopen_2020_047588 crossref_primary_10_1016_j_apsb_2022_12_006 crossref_primary_10_1016_j_intimp_2024_111812 crossref_primary_10_1016_j_dsx_2023_102921 crossref_primary_10_1038_s41598_023_33964_9 crossref_primary_10_1155_2020_8786424 crossref_primary_10_3389_fnut_2021_756565 crossref_primary_10_3390_computers12010019 crossref_primary_10_1016_j_phymed_2019_153082 crossref_primary_10_1016_j_jnutbio_2022_109157 crossref_primary_10_1002_hep_32139 crossref_primary_10_1016_j_ejmech_2020_112311 crossref_primary_10_1186_s12889_024_19882_z crossref_primary_10_1002_hep_31202 crossref_primary_10_1038_s41419_021_03514_0 crossref_primary_10_1007_s00109_022_02282_4 crossref_primary_10_1161_HYPERTENSIONAHA_119_13419 crossref_primary_10_1007_s42995_023_00168_z crossref_primary_10_1186_s12967_023_04790_4 crossref_primary_10_1016_j_molmet_2021_101428 crossref_primary_10_1016_j_ijbiomac_2024_134363 crossref_primary_10_1039_D2LC00940D crossref_primary_10_1016_j_lfs_2019_116829 crossref_primary_10_4254_wjh_v16_i12_1395 crossref_primary_10_1002_hep_30485 crossref_primary_10_1016_j_jlr_2024_100513 crossref_primary_10_1093_jpp_rgad044 crossref_primary_10_1002_hep_32045 crossref_primary_10_1002_med_21991 crossref_primary_10_1016_j_cmet_2020_03_007 crossref_primary_10_4108_eetpht_9_4379 crossref_primary_10_1155_2022_4138555 crossref_primary_10_1021_acs_jcim_9b00838 crossref_primary_10_34172_aim_31269 crossref_primary_10_1002_hep_31863 crossref_primary_10_1080_10715762_2023_2226315 crossref_primary_10_1002_clc_24205 crossref_primary_10_1007_s11418_019_01316_5 crossref_primary_10_1002_hep_31242 crossref_primary_10_1002_ctm2_1529 crossref_primary_10_3748_wjg_v30_i45_4791 crossref_primary_10_3727_105221619X15553433838609 crossref_primary_10_1002_hep4_1831 crossref_primary_10_1002_ptr_7762 crossref_primary_10_1007_s12272_019_01178_1 crossref_primary_10_1002_ar_24770 crossref_primary_10_1186_s12876_021_01824_3 crossref_primary_10_3727_105221619X15536120524171 crossref_primary_10_1097_MEG_0000000000002636 crossref_primary_10_1002_hep_32061 crossref_primary_10_1097_CP9_0000000000000104 crossref_primary_10_1186_s12967_022_03611_4 crossref_primary_10_3389_fendo_2023_1167608 crossref_primary_10_1111_bph_16342 crossref_primary_10_3390_antiox11061093 crossref_primary_10_1002_ptr_7195 crossref_primary_10_1016_j_ejphar_2022_175378 crossref_primary_10_3389_fgene_2024_1428334 crossref_primary_10_1002_fsn3_4144 crossref_primary_10_1002_hep_30559 crossref_primary_10_1007_s10552_024_01865_5 crossref_primary_10_3389_fgene_2018_00527 crossref_primary_10_1097_CM9_0000000000002277 crossref_primary_10_1080_17474124_2020_1820321 crossref_primary_10_1016_j_fitote_2024_106186 crossref_primary_10_3748_wjg_v25_i11_1307 crossref_primary_10_1080_21655979_2021_1933302 crossref_primary_10_1161_CIRCRESAHA_124_324383 crossref_primary_10_3389_fphar_2024_1360974 crossref_primary_10_3389_fphar_2023_1148737 crossref_primary_10_1155_2022_2386212 crossref_primary_10_1007_s12072_022_10395_8 crossref_primary_10_1186_s12944_020_01419_z crossref_primary_10_1080_15376516_2023_2202784 crossref_primary_10_1155_2021_8894685 crossref_primary_10_1016_j_ijbiomac_2024_136186 crossref_primary_10_1016_j_lfs_2020_117514 crossref_primary_10_1073_pnas_2018069118 crossref_primary_10_1016_j_imu_2023_101315 crossref_primary_10_1016_j_jep_2020_112569 crossref_primary_10_3892_ijmm_2019_4375 crossref_primary_10_1016_j_amjms_2024_10_005 crossref_primary_10_4254_wjh_v14_i4_791 crossref_primary_10_54393_pjhs_v5i10_2145 crossref_primary_10_1016_j_atherosclerosis_2022_07_010 crossref_primary_10_1002_hep_31773 |
| Cites_doi | 10.1016/j.jhep.2017.09.021 10.3109/00365521.2012.719926 10.1038/d41586-017-06927-0 10.1111/liv.12226 10.1016/j.dld.2011.04.013 10.1038/ajg.2010.475 10.1016/j.jhep.2017.12.030 10.1038/550S102a 10.1038/nm.4334 10.1038/nrgastro.2017.109 10.1038/nm.4461 10.1111/j.1440-1746.2009.05914.x 10.1074/jbc.M113.542399 10.1161/HYPERTENSIONAHA.116.08192 10.1002/hep.28940 10.1002/hep.28337 10.1016/j.cgh.2014.04.014 10.1007/s00125-015-3613-9 10.1161/CIRCULATIONAHA.110.990333 10.1055/s-0030-1247133 10.1053/j.gastro.2016.10.026 10.3748/wjg.v21.i4.1189 10.1146/annurev-med-051215-031109 10.1053/j.gastro.2009.01.053 10.1002/dmrr.1291 10.1200/JCO.2011.36.0917 10.1016/j.jhep.2016.07.033 10.1152/ajpgi.00199.2004 10.1038/nrendo.2017.173 10.1038/nm.4290 10.1038/nm.4459 10.1016/j.jhep.2018.01.019 10.1016/j.jhep.2015.11.004 10.1080/09637486.2016.1261086 10.1053/j.gastro.2010.09.038 10.1001/jama.2015.5370 10.7150/ijbs.13371 10.1016/j.jhep.2016.04.023 10.1038/ncomms10592 10.1038/nm.4453 10.1002/hep.20672 10.1002/hep.22734 10.1038/ajg.2013.5 10.1152/ajpgi.00304.2014 10.1097/MEG.0000000000000917 10.1038/nm.4451 10.1111/apt.12046 10.1053/j.gastro.2005.04.014 10.1002/hep.27173 10.1016/j.cld.2015.10.010 10.1161/CIRCULATIONAHA.109.192644 10.1002/hep.24127 10.1038/nrd.2015.3 10.1111/imj.13667 10.1007/s10620-014-3031-8 10.1152/ajpendo.00505.2012 10.3748/wjg.v23.i36.6571 10.1194/jlr.M007096 10.1038/ijo.2015.85 10.1111/hepr.12656 10.1002/hep.24001 10.1002/hep.20701 10.1016/j.jhep.2013.07.042 10.1016/j.bbrc.2006.02.032 10.1016/j.metabol.2017.09.010 10.1111/j.1365-2036.2009.03961.x 10.1002/hep.25805 10.1097/MCG.0000000000000075 10.1007/978-3-319-48382-5_19 10.1002/hep.28971 10.1054/bjoc.2000.1716 10.1111/jgh.13264 10.1002/hep.28785 10.1016/j.molmet.2015.09.013 10.1002/hep.26751 10.1016/j.ajpath.2015.12.028 10.1016/j.jhep.2016.06.005 10.1152/ajpendo.00470.2014 10.1038/nrgastro.2017.144 10.1016/j.atherosclerosis.2015.02.049 10.1002/hep.26368 10.1016/j.jhep.2009.12.042 10.1038/hr.2010.45 10.1002/hep.28555 10.1016/j.gcb.2010.06.004 10.1016/j.jhep.2013.05.044 10.1016/j.cgh.2011.01.023 10.1016/j.jhep.2017.10.006 10.1007/s10753-017-0528-2 10.1056/NEJMra1503519 10.3390/nu9091041 10.1002/hep.28431 10.1136/bmjopen-2015-008204 10.1002/hep.26248 10.1038/nm.4346 10.1136/bmj.i4428 10.1016/j.cmet.2016.11.009 10.1016/j.metabol.2015.12.012 10.1111/j.1365-2613.2011.00793.x 10.1016/j.dld.2017.01.147 10.1002/hep.28368 10.1136/gutjnl-2011-301708 10.1016/j.cgh.2014.08.013 10.1080/17474124.2018.1415756 10.1002/hep.29367 10.1016/j.jhep.2016.05.005 10.1016/j.jhep.2017.10.031 10.1016/j.jhep.2014.11.034 10.1056/NEJMoa0907929 10.1016/j.jhep.2012.03.019 10.1038/nrgastro.2017.181 10.1002/hep.510270601 10.1038/550S101a 10.1002/hep4.1079 10.1111/j.1445-5994.2012.02848.x 10.1016/j.jhep.2017.09.003 10.1016/j.jhep.2017.10.015 10.1111/j.1478-3231.2008.01706.x 10.1007/s00535-011-0431-9 10.1002/hep.29633 |
| ContentType | Journal Article |
| Copyright | 2018 Wiley Periodicals, Inc. Copyright © 2018 Wiley Periodicals, Inc. |
| Copyright_xml | – notice: 2018 Wiley Periodicals, Inc. – notice: Copyright © 2018 Wiley Periodicals, Inc. |
| DBID | AAYXX CITATION NPM K9. 7X8 |
| DOI | 10.1002/med.21515 |
| DatabaseName | CrossRef PubMed ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
| DatabaseTitle | CrossRef PubMed ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed CrossRef ProQuest Health & Medical Complete (Alumni) |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1098-1128 |
| EndPage | 348 |
| ExternalDocumentID | 29846945 10_1002_med_21515 MED21515 |
| Genre | reviewArticle Research Support, Non-U.S. Gov't Journal Article Review |
| GrantInformation_xml | – fundername: National Science and Technology Support Project funderid: 2014BAI02B01; 2015BAI08B01 – fundername: National Science Fund for Distinguished Young Scholars funderid: 81425005 – fundername: National Key Research and Development Program funderid: 2013YQ030923‐05 – fundername: Key Project of the National Natural Science Foundation funderid: 81330005; 81630011 – fundername: Key Collaborative Project of the National Natural Science Foundation funderid: 91639304 |
| GroupedDBID | --- .3N .GA .GJ .Y3 05W 0R~ 10A 1L6 1OB 1OC 1ZS 31~ 33P 3SF 3WU 4.4 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAMNL AANHP AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABEML ABIJN ABJNI ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACFBH ACGFO ACGFS ACGOF ACMXC ACPOU ACRPL ACSCC ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZMN AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFPM AFGKR AFPWT AFWVQ AFZJQ AHBTC AHMBA AIACR AIAGR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EBD EBS EJD EMOBN F00 F01 F04 F5P FEDTE FUBAC G-S G.N GNP GODZA GWYGA H.X HBH HF~ HGLYW HHZ HVGLF HZ~ IX1 J0M JPC KBYEO KQQ LATKE LAW LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LSO LUTES LW6 LYRES M6Q MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ NNB O66 O9- OIG P2P P2W P2X P2Z P4B P4D PALCI PQQKQ Q.N Q11 QB0 QRW R.K RIWAO RJQFR ROL RWI RX1 SAMSI SUPJJ SV3 UB1 V8K W8V W99 WBFHL WBKPD WIB WIH WIJ WIK WJL WOHZO WQJ WRC WUP WWP WXI WXSBR WYISQ XG1 XV2 YCJ ZGI ZZTAW ~IA ~WT AAYXX ADXHL AEYWJ AGHNM AGQPQ AGYGG CITATION AAMMB AEFGJ AGXDD AIDQK AIDYY NPM K9. 7X8 |
| ID | FETCH-LOGICAL-c3535-f98e8d41de19f967015c0c1669ba1b334ae2810a0d347f7e683d1b37060d7d3a3 |
| IEDL.DBID | DR2 |
| ISSN | 0198-6325 1098-1128 |
| IngestDate | Fri Jul 11 11:23:56 EDT 2025 Sun Jul 13 04:11:33 EDT 2025 Mon Jul 21 05:29:53 EDT 2025 Tue Jul 01 02:04:05 EDT 2025 Thu Apr 24 23:07:20 EDT 2025 Wed Jan 22 16:21:40 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | epidemiology nonalcoholic fatty liver disease (NAFLD) awareness animal model molecular target |
| Language | English |
| License | 2018 Wiley Periodicals, Inc. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c3535-f98e8d41de19f967015c0c1669ba1b334ae2810a0d347f7e683d1b37060d7d3a3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 |
| ORCID | 0000-0003-2466-754X |
| PMID | 29846945 |
| PQID | 2148743492 |
| PQPubID | 1016383 |
| PageCount | 21 |
| ParticipantIDs | proquest_miscellaneous_2047257547 proquest_journals_2148743492 pubmed_primary_29846945 crossref_citationtrail_10_1002_med_21515 crossref_primary_10_1002_med_21515 wiley_primary_10_1002_med_21515_MED21515 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | January 2019 2019-01-00 20190101 |
| PublicationDateYYYYMMDD | 2019-01-01 |
| PublicationDate_xml | – month: 01 year: 2019 text: January 2019 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Hoboken |
| PublicationTitle | Medicinal research reviews |
| PublicationTitleAlternate | Med Res Rev |
| PublicationYear | 2019 |
| Publisher | Wiley Subscription Services, Inc |
| Publisher_xml | – name: Wiley Subscription Services, Inc |
| References | 2017; 40 2004; 287 2015; 39 2017; 1 2017; 49 2013; 62 2011; 53 2018; 81 2016; 31 2015; 309 2015; 308 2017; 152 2017; 550 2017; 551 2012; 57 2012; 56 2014; 60 2009; 49 2017; 9 2001; 84 2016; 186 2018; 48 2011; 124 2013; 59 2015; 49 2013; 58 2008; 28 2016; 354 2014; 59 2012; 28 2009; 120 2017; 960 2010; 30 2016; 46 2014; 289 2015; 240 2015; 13 1998; 27 2010; 33 2009; 24 2015; 58 2013; 48 2015; 5 2015; 4 2013; 43 2013; 108 2017; 69 2017; 25 2017; 65 2017; 68 2015; 11 2017; 23 2005; 41 2010; 362 2011; 35 2017; 29 2012; 36 2018; 67 2017; 377 2016; 15 2009; 136 2009; 29 2012; 30 2018; 68 2011; 9 2018; 24 2016; 7 2011; 106 2017; 15 2013; 33 2017; 14 2015; 313 2015; 62 2011; 92 2015; 21 2013; 30 2016; 65 2005; 129 2016; 64 2016; 20 2016; 63 2017 2011; 43 2011; 46 2018; 12 2011; 140 2010; 52 2018; 15 2010; 51 2006; 342 2018; 14 e_1_2_12_6_1 e_1_2_12_2_1 e_1_2_12_17_1 e_1_2_12_111_1 e_1_2_12_115_1 e_1_2_12_108_1 e_1_2_12_20_1 e_1_2_12_66_1 e_1_2_12_43_1 e_1_2_12_85_1 e_1_2_12_24_1 e_1_2_12_47_1 e_1_2_12_89_1 e_1_2_12_62_1 e_1_2_12_81_1 e_1_2_12_100_1 e_1_2_12_123_1 Brody H (e_1_2_12_8_1) 2017; 551 e_1_2_12_28_1 e_1_2_12_104_1 e_1_2_12_31_1 e_1_2_12_77_1 e_1_2_12_54_1 e_1_2_12_96_1 e_1_2_12_35_1 e_1_2_12_58_1 e_1_2_12_12_1 e_1_2_12_73_1 e_1_2_12_50_1 e_1_2_12_92_1 e_1_2_12_3_1 e_1_2_12_18_1 e_1_2_12_110_1 e_1_2_12_114_1 e_1_2_12_21_1 e_1_2_12_44_1 e_1_2_12_63_1 e_1_2_12_86_1 e_1_2_12_107_1 e_1_2_12_25_1 e_1_2_12_48_1 e_1_2_12_67_1 e_1_2_12_40_1 e_1_2_12_82_1 e_1_2_12_122_1 e_1_2_12_29_1 Younossi ZM (e_1_2_12_14_1) 2017 e_1_2_12_103_1 e_1_2_12_119_1 e_1_2_12_32_1 e_1_2_12_55_1 e_1_2_12_74_1 e_1_2_12_97_1 e_1_2_12_36_1 e_1_2_12_59_1 e_1_2_12_78_1 e_1_2_12_13_1 e_1_2_12_7_1 e_1_2_12_51_1 e_1_2_12_70_1 e_1_2_12_93_1 e_1_2_12_4_1 e_1_2_12_19_1 e_1_2_12_38_1 e_1_2_12_113_1 e_1_2_12_41_1 e_1_2_12_87_1 e_1_2_12_106_1 e_1_2_12_22_1 e_1_2_12_64_1 e_1_2_12_45_1 e_1_2_12_26_1 e_1_2_12_68_1 e_1_2_12_83_1 e_1_2_12_60_1 Younossi ZM (e_1_2_12_15_1) 2017 e_1_2_12_49_1 e_1_2_12_121_1 e_1_2_12_102_1 e_1_2_12_52_1 e_1_2_12_98_1 e_1_2_12_118_1 e_1_2_12_33_1 e_1_2_12_75_1 e_1_2_12_56_1 e_1_2_12_37_1 e_1_2_12_79_1 e_1_2_12_90_1 e_1_2_12_10_1 e_1_2_12_94_1 e_1_2_12_71_1 e_1_2_12_5_1 e_1_2_12_16_1 e_1_2_12_112_1 e_1_2_12_39_1 e_1_2_12_116_1 e_1_2_12_42_1 e_1_2_12_65_1 e_1_2_12_88_1 e_1_2_12_109_1 e_1_2_12_23_1 e_1_2_12_46_1 e_1_2_12_69_1 e_1_2_12_80_1 e_1_2_12_61_1 e_1_2_12_84_1 e_1_2_12_27_1 e_1_2_12_101_1 e_1_2_12_120_1 e_1_2_12_105_1 e_1_2_12_124_1 e_1_2_12_30_1 e_1_2_12_53_1 e_1_2_12_76_1 e_1_2_12_99_1 e_1_2_12_117_1 e_1_2_12_34_1 e_1_2_12_57_1 e_1_2_12_91_1 e_1_2_12_11_1 e_1_2_12_72_1 e_1_2_12_95_1 e_1_2_12_9_1 |
| References_xml | – volume: 12 start-page: 351 year: 2018 end-page: 367 article-title: Clinical relevance of liver histopathology and different histological classifications of NASH in adults publication-title: Expert Rev Gastroenterol Hepatol – volume: 28 start-page: 856 year: 2008 end-page: 864 article-title: Macaca radiata (bonnet monkey): a spontaneous model of nonalcoholic fatty liver disease publication-title: Liver Int – volume: 29 start-page: 1019 year: 2009 end-page: 1024 article-title: Screening for hepatitis b, c and non‐alcoholic fatty liver disease: a survey of community‐based physicians publication-title: Aliment Pharmacol Ther – volume: 68 start-page: 230 year: 2018 end-page: 237 article-title: Preclinical models of non‐alcoholic fatty liver disease publication-title: J Hepatol – volume: 960 start-page: 443 year: 2017 end-page: 467 article-title: Non‐alcoholic fatty liver disease publication-title: Adv Exp Med Biol – volume: 68 start-page: 268 year: 2018 end-page: 279 article-title: Genetics and epigenetics of NAFLD and NASH: clinical impact publication-title: J Hepatol – volume: 152 start-page: 598 year: 2017 end-page: 607 article-title: Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy‐proven nonalcoholic fatty liver disease publication-title: Gastroenterology – volume: 140 start-page: 124 year: 2011 end-page: 131 article-title: Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle‐aged population utilizing ultrasound and liver biopsy: a prospective study publication-title: Gastroenterology – volume: 60 start-page: 565 year: 2014 end-page: 575 article-title: Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease publication-title: Hepatology – volume: 65 start-page: 1006 year: 2016 end-page: 1016 article-title: Mri and mre for non‐invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: clinical trials to clinical practice publication-title: J Hepatol – volume: 68 start-page: 455 year: 2017 end-page: 466 article-title: Hepatic rhythmicity of endoplasmic reticulum stress is disrupted in perinatal and adult mice models of high‐fat diet‐induced obesity publication-title: Int J Food Sci Nutr – volume: 65 start-page: 1492 year: 2017 end-page: 1511 article-title: The E3 ligase tripartite motif 8 targets TAK1 to promote insulin resistance and steatohepatitis publication-title: Hepatology – volume: 33 start-page: 1398 year: 2013 end-page: 1405 article-title: Predictive value of alt levels for non‐alcoholic steatohepatitis (NASH) and advanced fibrosis in non‐alcoholic fatty liver disease (NAFLD) publication-title: Liver Int – volume: 68 start-page: 1063 year: 2018 end-page: 1075 article-title: Fructose and sugar: a major mediator of nonalcoholic fatty liver disease publication-title: J Hepatol – volume: 287 start-page: G1035 year: 2004 end-page: G1043 article-title: Obese and diabetic db/db mice develop marked liver fibrosis in a model of nonalcoholic steatohepatitis: role of short‐form leptin receptors and osteopontin publication-title: Am J Physiol Gastrointest Liver Physiol – volume: 15 start-page: 249 year: 2016 end-page: 274 article-title: Non‐alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies publication-title: Nat Rev Drug Discov – volume: 58 start-page: 1868 year: 2015 end-page: 1876 article-title: Oncostatin M is a potential agent for the treatment of obesity and related metabolic disorders: a study in mice publication-title: Diabetologia – volume: 9 start-page: pii year: 2017 article-title: Developmental programming of obesity and liver metabolism by maternal perinatal nutrition involves the melanocortin system publication-title: Nutrients – volume: 65 start-page: 570 year: 2016 end-page: 578 article-title: Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by fibroscan in non‐alcoholic fatty liver disease publication-title: J Hepatol – volume: 309 start-page: G270 year: 2015 end-page: G278 article-title: Hepatic TLR4 signaling in obese NAFLD publication-title: Am J Physiol Gastrointest Liver Physiol – volume: 69 start-page: 747 year: 2017 end-page: 760 article-title: Reprogramming innate immune signaling in cardiometabolic disease publication-title: Hypertension – volume: 46 start-page: 1230 year: 2011 end-page: 1237 article-title: Hepatocellular carcinoma in japanese patients with nonalcoholic fatty liver disease, alcoholic liver disease, and chronic liver disease of unknown etiology: report of the nationwide survey publication-title: J Gastroenterol – volume: 21 start-page: 1189 year: 2015 end-page: 1196 article-title: Characteristics of hepatocellular carcinoma in cirrhotic and non‐cirrhotic non‐alcoholic fatty liver disease publication-title: World J Gastroenterol – volume: 64 start-page: 73 year: 2016 end-page: 84 article-title: Global epidemiology of nonalcoholic fatty liver disease‐meta‐analytic assessment of prevalence, incidence, and outcomes publication-title: Hepatology – volume: 25 start-page: 412 year: 2017 end-page: 427 article-title: SREBP1 contributes to resolution of pro‐inflammatory TLR4 signaling by reprogramming fatty acid metabolism publication-title: Cell Metab – volume: 550 start-page: S102 year: 2017 end-page: S103 article-title: Fighting the fatty liver publication-title: Nature – volume: 377 start-page: 2063 year: 2017 end-page: 2072 article-title: Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis publication-title: N Engl J Med – volume: 43 start-page: 736 year: 2011 end-page: 741 article-title: Management of chronic liver disease by general practitioners in southern italy: unmet educational needs publication-title: Dig Liver Dis – volume: 52 start-page: 1836 year: 2010 end-page: 1846 article-title: Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis publication-title: Hepatology – volume: 64 start-page: 1388 year: 2016 end-page: 1402 article-title: EASL‐EASD‐EASO clinical practice guidelines for the management of non‐alcoholic fatty liver disease publication-title: J Hepatol – volume: 24 start-page: 73 year: 2018 end-page: 83 article-title: An ALOX12‐12‐HETE‐GPR31 signaling axis is a key mediator of hepatic ischemia‐reperfusion injury publication-title: Nat Med – volume: 49 start-page: 851 year: 2009 end-page: 859 article-title: Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis publication-title: Hepatology – volume: 15 start-page: 11 year: 2017 end-page: 20 article-title: Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention publication-title: Nat Rev Gastroenterol Hepatol – volume: 14 start-page: 99 year: 2018 end-page: 114 article-title: Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus publication-title: Nat Rev Endocrinol – volume: 4 start-page: 951 year: 2015 end-page: 960 article-title: Hepatocyte TRAF3 promotes insulin resistance and type 2 diabetes in mice with obesity publication-title: Mol Metab – volume: 43 start-page: 247 year: 2013 end-page: 253 article-title: Awareness and opinions of non‐alcoholic fatty liver disease by hospital specialists publication-title: Intern Med J – volume: 63 start-page: 827 year: 2016 end-page: 838 article-title: Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: a multicenter prospective study publication-title: Hepatology – volume: 67 start-page: 328 year: 2018 end-page: 357 article-title: The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the american association for the study of liver diseases publication-title: Hepatology – volume: 40 start-page: 840 year: 2017 end-page: 848 article-title: A20 attenuates liver fibrosis in NAFLD and inhibits inflammation responses publication-title: Inflammation – year: 2017 article-title: Current and future therapeutic regimens for non‐alcoholic fatty liver disease (NAFLD) and non‐alcoholic steatohepatitis (NASH) publication-title: Hepatology – volume: 24 start-page: 84 year: 2018 end-page: 94 article-title: The deubiquitinating enzyme TNFAIP3 mediates inactivation of hepatic ASK1 and ameliorates nonalcoholic steatohepatitis publication-title: Nat Med – volume: 59 start-page: 870 year: 2014 end-page: 85 article-title: Interferon regulatory factor 3 constrains IKKβ/NF‐κB signaling to alleviate hepatic steatosis and insulin resistance publication-title: Hepatology – volume: 64 start-page: 1577 year: 2016 end-page: 1586 article-title: The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe publication-title: Hepatology – volume: 106 start-page: 894 year: 2011 end-page: 898 article-title: Statin use and the risk of liver cancer: a population‐based case‐control study publication-title: Am J Gastroenterol – volume: 354 start-page: i4428 year: 2016 article-title: Non‐alcoholic fatty liver disease (NAFLD): summary of nice guidance publication-title: BMJ – volume: 57 start-page: 376 year: 2012 end-page: 383 article-title: A survey of patterns of practice and perception of NAFLD in a large sample of practicing gastroenterologists in france publication-title: J Hepatol – volume: 362 start-page: 1675 year: 2010 end-page: 1685 article-title: Pioglitazone, vitamin e, or placebo for nonalcoholic steatohepatitis publication-title: N Engl J Med – volume: 108 start-page: 881 year: 2013 end-page: 891 article-title: Anti‐diabetic medications and the risk of hepatocellular cancer: a systematic review and meta‐analysis publication-title: Am J Gastroenterol – volume: 124 start-page: 77 year: 2011 end-page: 86 article-title: Rhesus macaques develop metabolic syndrome with reversible vascular dysfunction responsive to pioglitazone publication-title: Circulation – volume: 33 start-page: 638 year: 2010 end-page: 643 article-title: Fatty liver incidence and predictive variables publication-title: Hypertens Res – volume: 48 start-page: 78 year: 2013 end-page: 87 article-title: Metformin and reduced risk of hepatocellular carcinoma in diabetic patients: a meta‐analysis publication-title: Scand J Gastroenterol – volume: 29 start-page: 1102 year: 2017 end-page: 1103 article-title: The impact of genetic polymorphisms on liver diseases: entering the era of personalized medicine publication-title: Eur J Gastroenterol Hepatol – volume: 49 start-page: e6 year: 2015 end-page: e10 article-title: Low awareness of nonalcoholic fatty liver disease among patients at high metabolic risk publication-title: J Clin Gastroenterol – volume: 27 start-page: 1463 year: 1998 end-page: 1466 article-title: Hepatic steatosis: innocent bystander or guilty party publication-title: Hepatology – volume: 23 start-page: 1385 year: 2017 article-title: Cutting out the liver fat publication-title: Nat Med – volume: 13 start-page: 594 year: 2015 end-page: 601 article-title: Temporal trends of nonalcoholic fatty liver disease‐related hepatocellular carcinoma in the veteran affairs population publication-title: Clin Gastroenterol Hepatol – volume: 15 start-page: 11 year: 2018 end-page: 20 article-title: Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention publication-title: Nat Rev Gastroenterol Hepatol – year: 2017 article-title: Diagnostic modalities for non‐alcoholic fatty liver disease (NAFLD), non‐alcoholic steatohepatitis (NASH) and associated fibrosis publication-title: Hepatology – volume: 68 start-page: 326 year: 2018 end-page: 334 article-title: Should we undertake surveillance for HCC in patients with NAFLD publication-title: J Hepatol – volume: 41 start-page: 1313 year: 2005 end-page: 1321 article-title: Design and validation of a histological scoring system for nonalcoholic fatty liver disease publication-title: Hepatology – volume: 24 start-page: 1786 year: 2009 end-page: 1790 article-title: Non‐alcoholic fatty liver disease: an expanding problem with low levels of awareness in hong kong publication-title: J Gastroenterol Hepatol – volume: 23 start-page: 829 year: 2017 end-page: 838 article-title: Thermoneutral housing exacerbates nonalcoholic fatty liver disease in mice and allows for sex‐independent disease modeling publication-title: Nat Med – volume: 11 start-page: 1436 year: 2015 end-page: 1446 article-title: A20 attenuates FFAs‐induced lipid accumulation in nonalcoholic steatohepatitis publication-title: Int J Biol Sci – volume: 81 start-page: 13 year: 2018 end-page: 24 article-title: Activation of the STING‐IRF3 pathway promotes hepatocyte inflammation, apoptosis and induces metabolic disorders in nonalcoholic fatty liver disease publication-title: Metabolism – volume: 35 start-page: 23 year: 2011 end-page: 28 article-title: Progression from isolated steatosis to steatohepatitis and fibrosis in nonalcoholic fatty liver disease publication-title: Clin Res Hepatol Gastroenterol – volume: 62 start-page: 1148 year: 2015 end-page: 1155 article-title: Evidence of NAFLD progression from steatosis to fibrosing‐steatohepatitis using paired biopsies: implications for prognosis and clinical management publication-title: J Hepatol – volume: 59 start-page: 1617 year: 2014 end-page: 1624 article-title: Oxnash score correlates with histologic features and severity of nonalcoholic fatty liver disease publication-title: Dig Dis Sci – volume: 28 start-page: 109 year: 2012 end-page: 122 article-title: Diabetes mellitus and risk of hepatocellular carcinoma: a systematic review and meta‐analysis publication-title: Diabetes Metab Res Rev – volume: 30 start-page: E485 year: 2013 end-page: E495 article-title: Interferon regulatory factor 7 deficiency prevents diet‐induced obesity and insulin resistance publication-title: Am J Physiol Endocrinol Metab – volume: 550 start-page: S101 year: 2017 article-title: Fatty liver disease: turning the tide publication-title: Nature – volume: 7 start-page: 10592 year: 2016 article-title: Hepatocyte TRAF3 promotes liver steatosis and systemic insulin resistance through targeting TAK1‐dependent signalling publication-title: Nat Commun – volume: 15 start-page: 71 year: 2018 end-page: 72 article-title: NAFLD in 2017: novel insights into mechanisms of disease progression publication-title: Nat Rev Gastroenterol Hepatol – volume: 551 year: 2017 article-title: Fatty liver disease publication-title: Nature – volume: 49 start-page: 471 year: 2017 end-page: 483 article-title: AISF position paper on nonalcoholic fatty liver disease (NAFLD): updates and future directions publication-title: Dig Liver Dis – volume: 64 start-page: 1386 year: 2016 end-page: 1387 article-title: The increasing burden of nonalcoholic fatty liver disease among young adults in the united states: a growing epidemic publication-title: Hepatology – volume: 58 start-page: 603 year: 2013 end-page: 616 article-title: Interferon regulatory factor 9 protects against hepatic insulin resistance and steatosis in male mice publication-title: Hepatology – volume: 60 start-page: 167 year: 2014 end-page: 174 article-title: Limited value of plasma cytokeratin‐18 as a biomarker for NASH and fibrosis in patients with non‐alcoholic fatty liver disease publication-title: J Hepatol – volume: 63 start-page: 453 year: 2016 end-page: 461 article-title: Magnetic resonance elastography is superior to acoustic radiation force impulse for the diagnosis of fibrosis in patients with biopsy‐proven nonalcoholic fatty liver disease: a prospective study publication-title: Hepatology – volume: 129 start-page: 113 year: 2005 end-page: 121 article-title: The natural history of nonalcoholic fatty liver disease: a population‐based cohort study publication-title: Gastroenterology – volume: 31 start-page: 936 year: 2016 end-page: 944 article-title: Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta‐analysis publication-title: J Gastroenterol Hepatol – volume: 36 start-page: 815 year: 2012 end-page: 823 article-title: Review article: is non‐alcoholic fatty liver disease a spectrum, or are steatosis and non‐alcoholic steatohepatitis distinct conditions publication-title: Aliment Pharmacol Ther – volume: 51 start-page: 3046 year: 2010 end-page: 3054 article-title: Mass spectrometric profiling of oxidized lipid products in human nonalcoholic fatty liver disease and nonalcoholic steatohepatitis publication-title: J Lipid Res – volume: 46 start-page: 1074 year: 2016 end-page: 1087 article-title: The independent predictors of non‐alcoholic steatohepatitis and its individual histological features: insulin resistance, serum uric acid, metabolic syndrome, alanine aminotransferase and serum total cholesterol are a clue to pathogenesis and candidate targets for treatment publication-title: Hepatol Res – volume: 59 start-page: 859 year: 2013 end-page: 871 article-title: From NAFLD in clinical practice to answers from guidelines publication-title: J Hepatol – volume: 308 start-page: E460 year: 2015 end-page: E469 article-title: Myeloid cell TRAF3 promotes metabolic inflammation, insulin resistance, and hepatic steatosis in obesity publication-title: Am J Physiol Endocrinol Metab – volume: 313 start-page: 2263 year: 2015 end-page: 2273 article-title: Nonalcoholic fatty liver disease: a systematic review publication-title: JAMA – volume: 13 start-page: 643 year: 2015 end-page: 654 article-title: Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta‐analysis of paired‐biopsy studies publication-title: Clin Gastroenterol Hepatol – volume: 92 start-page: 413 year: 2011 end-page: 421 article-title: Pathology of the liver in obese and diabetic ob/ob and db/db mice fed a standard or high‐calorie diet publication-title: Int J Exp Pathol – volume: 65 start-page: 1245 year: 2016 end-page: 1257 article-title: NAFLD and liver transplantation: current burden and expected challenges publication-title: J Hepatol – volume: 48 start-page: 144 year: 2018 end-page: 151 article-title: Underappreciation of non‐alcoholic fatty liver disease by primary care clinicians: limited awareness of surrogate markers of fibrosis publication-title: Intern Med J – volume: 68 start-page: 85 year: 2017 end-page: 98 article-title: Nonalcoholic steatohepatitis publication-title: Annu Rev Med – volume: 68 start-page: 1093 year: 2018 end-page: 1094 article-title: The role of NAFLD in extrahepatic malignancies: the importance of ruling out the effect of obesity publication-title: J Hepatol – volume: 120 start-page: 1640 year: 2009 end-page: 1645 article-title: Harmonizing the metabolic syndrome: aA joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity publication-title: Circulation – volume: 289 start-page: 13821 year: 2014 end-page: 13837 article-title: Deficiency of oncostatin M receptor β (OSMRβ) exacerbates high‐fat diet‐induced obesity and related metabolic disorders in mice publication-title: J Biol Chem – volume: 65 start-page: 1078 year: 2017 article-title: The increasing burden of NAFLD fibrosis in the general population: time to bridge the gap between hepatologists and primary care publication-title: Hepatology – volume: 23 start-page: 439 year: 2017 end-page: 449 article-title: Targeting casp8 and fadd‐like apoptosis regulator ameliorates nonalcoholic steatohepatitis in mice and nonhuman primates publication-title: Nat Med – volume: 24 start-page: 213 year: 2018 end-page: 223 article-title: The deubiquitinating enzyme cylindromatosis mitigates nonalcoholic steatohepatitis publication-title: Nat Med – volume: 186 start-page: 1278 year: 2016 end-page: 1292 article-title: Hepatic oncostatin m receptor beta regulates obesity‐induced steatosis and insulin resistance publication-title: Am J Pathol – volume: 23 start-page: 6571 year: 2017 end-page: 6592 article-title: Nonalcoholic fatty liver disease: evolving paradigms publication-title: World J Gastroenterol – volume: 68 start-page: 362 year: 2018 end-page: 375 article-title: Pharmacotherapy for NASH: current and emerging publication-title: J Hepatol – volume: 9 start-page: 428 year: 2011 end-page: 433 article-title: Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma publication-title: Clin Gastroenterol Hepatol – volume: 23 start-page: 742 year: 2017 end-page: 752 article-title: Tmbim1 is a multivesicular body regulator that protects against non‐alcoholic fatty liver disease in mice and monkeys by targeting the lysosomal degradation of tlr4 publication-title: Nat Med – volume: 5 start-page: e008204 year: 2015 article-title: Identification of reciprocal causality between non‐alcoholic fatty liver disease and metabolic syndrome by a simplified bayesian network in a chinese population publication-title: BMJ Open – volume: 14 start-page: 631 year: 2017 article-title: NAFLD: early promise for ask1 inhibition in NASH publication-title: Nat Rev Gastroenterol Hepatol – volume: 67 start-page: 1303 year: 2018 end-page: 1319 article-title: Hepatic leukocyte immunoglobulin‐like receptor B4 (LILRB4) attenuates nonalcoholic fatty liver disease via SHP1‐TRAF6 pathway publication-title: Hepatology – volume: 136 start-page: 1601 year: 2009 end-page: 1608 article-title: Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes publication-title: Gastroenterology – volume: 30 start-page: 61 year: 2010 end-page: 74 article-title: Current strategy for staging and treatment: the BCLC update and future prospects publication-title: Semin Liver Dis – volume: 58 start-page: 128 year: 2013 end-page: 138 article-title: Maternal obesity programs offspring nonalcoholic fatty liver disease by innate immune dysfunction in mice publication-title: Hepatology – volume: 52 start-page: 913 year: 2010 end-page: 920 article-title: Maternal obesity during pregnancy and lactation programs the development of offspring non‐alcoholic fatty liver disease in mice publication-title: J Hepatol – volume: 65 start-page: 579 year: 2016 end-page: 588 article-title: A diet‐induced animal model of non‐alcoholic fatty liver disease and hepatocellular cancer publication-title: J Hepatol – volume: 68 start-page: 335 year: 2018 end-page: 352 article-title: Hypertension, diabetes, atherosclerosis and NASH: cause or consequence publication-title: J Hepatol – volume: 39 start-page: 1339 year: 2015 end-page: 1348 article-title: Maternal obesity programs offspring non‐alcoholic fatty liver disease through disruption of 24‐h rhythms in mice publication-title: Int J Obes – volume: 41 start-page: 753 year: 2005 end-page: 760 article-title: Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy publication-title: Hepatology – volume: 53 start-page: 810 year: 2011 end-page: 820 article-title: Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings publication-title: Hepatology – volume: 240 start-page: 144 year: 2015 end-page: 148 article-title: Metabolic syndrome and its components as predictors of nonalcoholic fatty liver disease in a northern urban han chinese population: a prospective cohort study publication-title: Atherosclerosis – volume: 65 start-page: 1038 year: 2016 end-page: 1048 article-title: The multiple‐hit pathogenesis of non‐alcoholic fatty liver disease (NAFLD) publication-title: Metabolism – volume: 342 start-page: 1152 year: 2006 end-page: 1159 article-title: Adaptive failure to high‐fat diet characterizes steatohepatitis in Alms1 mutant mice publication-title: Biochem Biophys Res Commun – volume: 56 start-page: 1311 year: 2012 end-page: 1318 article-title: Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis: a pioglitazone versus vitamin e versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis trial follow‐up study publication-title: Hepatology – volume: 30 start-page: 623 year: 2012 end-page: 630 article-title: Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection publication-title: J Clin Oncol – volume: 20 start-page: 313 year: 2016 end-page: 324 article-title: Progression and natural history of nonalcoholic fatty liver disease in adults publication-title: Clin Liver Dis – volume: 1 start-page: 577 year: 2017 end-page: 585 article-title: Clinical endpoints and adaptive clinical trials in precirrhotic nonalcoholic steatohepatitis: facilitating development approaches for an emerging epidemic publication-title: Hepatol Commun – volume: 84 start-page: 886 year: 2001 end-page: 891 article-title: Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial publication-title: Br J Cancer. – volume: 62 start-page: 606 year: 2013 end-page: 615 article-title: Metformin decreases hepatocellular carcinoma risk in a dose‐dependent manner: population‐based and in vitro studies publication-title: Gut – ident: e_1_2_12_5_1 doi: 10.1016/j.jhep.2017.09.021 – ident: e_1_2_12_81_1 doi: 10.3109/00365521.2012.719926 – volume: 551 year: 2017 ident: e_1_2_12_8_1 article-title: Fatty liver disease publication-title: Nature doi: 10.1038/d41586-017-06927-0 – ident: e_1_2_12_64_1 doi: 10.1111/liv.12226 – ident: e_1_2_12_34_1 doi: 10.1016/j.dld.2011.04.013 – ident: e_1_2_12_84_1 doi: 10.1038/ajg.2010.475 – ident: e_1_2_12_17_1 doi: 10.1016/j.jhep.2017.12.030 – ident: e_1_2_12_10_1 doi: 10.1038/550S102a – ident: e_1_2_12_99_1 doi: 10.1038/nm.4334 – ident: e_1_2_12_12_1 doi: 10.1038/nrgastro.2017.109 – ident: e_1_2_12_101_1 doi: 10.1038/nm.4461 – ident: e_1_2_12_28_1 doi: 10.1111/j.1440-1746.2009.05914.x – ident: e_1_2_12_122_1 doi: 10.1074/jbc.M113.542399 – ident: e_1_2_12_106_1 doi: 10.1161/HYPERTENSIONAHA.116.08192 – ident: e_1_2_12_36_1 doi: 10.1002/hep.28940 – ident: e_1_2_12_60_1 doi: 10.1002/hep.28337 – ident: e_1_2_12_22_1 doi: 10.1016/j.cgh.2014.04.014 – ident: e_1_2_12_123_1 doi: 10.1007/s00125-015-3613-9 – ident: e_1_2_12_98_1 doi: 10.1161/CIRCULATIONAHA.110.990333 – year: 2017 ident: e_1_2_12_15_1 article-title: Current and future therapeutic regimens for non‐alcoholic fatty liver disease (NAFLD) and non‐alcoholic steatohepatitis (NASH) publication-title: Hepatology – ident: e_1_2_12_52_1 doi: 10.1055/s-0030-1247133 – ident: e_1_2_12_66_1 doi: 10.1053/j.gastro.2016.10.026 – ident: e_1_2_12_47_1 doi: 10.3748/wjg.v21.i4.1189 – ident: e_1_2_12_87_1 doi: 10.1146/annurev-med-051215-031109 – ident: e_1_2_12_83_1 doi: 10.1053/j.gastro.2009.01.053 – ident: e_1_2_12_78_1 doi: 10.1002/dmrr.1291 – ident: e_1_2_12_85_1 doi: 10.1200/JCO.2011.36.0917 – ident: e_1_2_12_26_1 doi: 10.1016/j.jhep.2016.07.033 – ident: e_1_2_12_94_1 doi: 10.1152/ajpgi.00199.2004 – ident: e_1_2_12_88_1 doi: 10.1038/nrendo.2017.173 – ident: e_1_2_12_97_1 doi: 10.1038/nm.4290 – ident: e_1_2_12_49_1 doi: 10.1038/nm.4459 – ident: e_1_2_12_16_1 doi: 10.1016/j.jhep.2018.01.019 – ident: e_1_2_12_3_1 doi: 10.1016/j.jhep.2015.11.004 – ident: e_1_2_12_73_1 doi: 10.1080/09637486.2016.1261086 – ident: e_1_2_12_27_1 doi: 10.1053/j.gastro.2010.09.038 – ident: e_1_2_12_30_1 doi: 10.1001/jama.2015.5370 – ident: e_1_2_12_120_1 doi: 10.7150/ijbs.13371 – ident: e_1_2_12_61_1 doi: 10.1016/j.jhep.2016.04.023 – ident: e_1_2_12_110_1 doi: 10.1038/ncomms10592 – ident: e_1_2_12_100_1 doi: 10.1038/nm.4453 – ident: e_1_2_12_92_1 doi: 10.1002/hep.20672 – ident: e_1_2_12_53_1 doi: 10.1002/hep.22734 – ident: e_1_2_12_80_1 doi: 10.1038/ajg.2013.5 – ident: e_1_2_12_109_1 doi: 10.1152/ajpgi.00304.2014 – ident: e_1_2_12_69_1 doi: 10.1097/MEG.0000000000000917 – ident: e_1_2_12_103_1 doi: 10.1038/nm.4451 – ident: e_1_2_12_42_1 doi: 10.1111/apt.12046 – ident: e_1_2_12_44_1 doi: 10.1053/j.gastro.2005.04.014 – ident: e_1_2_12_58_1 doi: 10.1002/hep.27173 – ident: e_1_2_12_54_1 doi: 10.1016/j.cld.2015.10.010 – ident: e_1_2_12_96_1 doi: 10.1161/CIRCULATIONAHA.109.192644 – ident: e_1_2_12_57_1 doi: 10.1002/hep.24127 – ident: e_1_2_12_104_1 doi: 10.1038/nrd.2015.3 – ident: e_1_2_12_32_1 doi: 10.1111/imj.13667 – ident: e_1_2_12_65_1 doi: 10.1007/s10620-014-3031-8 – ident: e_1_2_12_116_1 doi: 10.1152/ajpendo.00505.2012 – ident: e_1_2_12_43_1 doi: 10.3748/wjg.v23.i36.6571 – ident: e_1_2_12_63_1 doi: 10.1194/jlr.M007096 – ident: e_1_2_12_70_1 doi: 10.1038/ijo.2015.85 – ident: e_1_2_12_18_1 doi: 10.1111/hepr.12656 – ident: e_1_2_12_40_1 doi: 10.1002/hep.24001 – ident: e_1_2_12_56_1 doi: 10.1002/hep.20701 – ident: e_1_2_12_62_1 doi: 10.1016/j.jhep.2013.07.042 – ident: e_1_2_12_95_1 doi: 10.1016/j.bbrc.2006.02.032 – ident: e_1_2_12_114_1 doi: 10.1016/j.metabol.2017.09.010 – ident: e_1_2_12_35_1 doi: 10.1111/j.1365-2036.2009.03961.x – ident: e_1_2_12_76_1 doi: 10.1002/hep.25805 – ident: e_1_2_12_29_1 doi: 10.1097/MCG.0000000000000075 – ident: e_1_2_12_105_1 doi: 10.1007/978-3-319-48382-5_19 – ident: e_1_2_12_121_1 doi: 10.1002/hep.28971 – ident: e_1_2_12_82_1 doi: 10.1054/bjoc.2000.1716 – ident: e_1_2_12_19_1 doi: 10.1111/jgh.13264 – ident: e_1_2_12_124_1 doi: 10.1002/hep.28785 – ident: e_1_2_12_112_1 doi: 10.1016/j.molmet.2015.09.013 – ident: e_1_2_12_115_1 doi: 10.1002/hep.26751 – ident: e_1_2_12_118_1 doi: 10.1016/j.ajpath.2015.12.028 – ident: e_1_2_12_59_1 doi: 10.1016/j.jhep.2016.06.005 – ident: e_1_2_12_111_1 doi: 10.1152/ajpendo.00470.2014 – ident: e_1_2_12_13_1 doi: 10.1038/nrgastro.2017.144 – ident: e_1_2_12_21_1 doi: 10.1016/j.atherosclerosis.2015.02.049 – ident: e_1_2_12_117_1 doi: 10.1002/hep.26368 – ident: e_1_2_12_2_1 doi: 10.1038/nrgastro.2017.109 – ident: e_1_2_12_72_1 doi: 10.1016/j.jhep.2009.12.042 – ident: e_1_2_12_23_1 doi: 10.1038/hr.2010.45 – ident: e_1_2_12_25_1 doi: 10.1002/hep.28555 – ident: e_1_2_12_41_1 doi: 10.1016/j.gcb.2010.06.004 – ident: e_1_2_12_38_1 doi: 10.1016/j.jhep.2013.05.044 – ident: e_1_2_12_50_1 doi: 10.1016/j.cgh.2011.01.023 – ident: e_1_2_12_4_1 doi: 10.1016/j.jhep.2017.10.006 – ident: e_1_2_12_119_1 doi: 10.1007/s10753-017-0528-2 – ident: e_1_2_12_7_1 doi: 10.1056/NEJMra1503519 – ident: e_1_2_12_71_1 doi: 10.3390/nu9091041 – ident: e_1_2_12_20_1 doi: 10.1002/hep.28431 – ident: e_1_2_12_24_1 doi: 10.1136/bmjopen-2015-008204 – ident: e_1_2_12_74_1 doi: 10.1002/hep.26248 – ident: e_1_2_12_107_1 doi: 10.1038/nm.4346 – ident: e_1_2_12_6_1 doi: 10.1136/bmj.i4428 – ident: e_1_2_12_108_1 doi: 10.1016/j.cmet.2016.11.009 – year: 2017 ident: e_1_2_12_14_1 article-title: Diagnostic modalities for non‐alcoholic fatty liver disease (NAFLD), non‐alcoholic steatohepatitis (NASH) and associated fibrosis publication-title: Hepatology – ident: e_1_2_12_68_1 doi: 10.1016/j.metabol.2015.12.012 – ident: e_1_2_12_93_1 doi: 10.1111/j.1365-2613.2011.00793.x – ident: e_1_2_12_37_1 doi: 10.1016/j.dld.2017.01.147 – ident: e_1_2_12_46_1 doi: 10.1002/hep.28368 – ident: e_1_2_12_79_1 doi: 10.1136/gutjnl-2011-301708 – ident: e_1_2_12_55_1 doi: 10.1016/j.cgh.2014.08.013 – ident: e_1_2_12_31_1 doi: 10.1080/17474124.2018.1415756 – ident: e_1_2_12_75_1 doi: 10.1002/hep.29367 – ident: e_1_2_12_91_1 doi: 10.1016/j.jhep.2016.05.005 – ident: e_1_2_12_90_1 doi: 10.1016/j.jhep.2017.10.031 – ident: e_1_2_12_48_1 doi: 10.1016/j.jhep.2014.11.034 – ident: e_1_2_12_77_1 doi: 10.1056/NEJMoa0907929 – ident: e_1_2_12_39_1 doi: 10.1016/j.jhep.2012.03.019 – ident: e_1_2_12_11_1 doi: 10.1038/nrgastro.2017.181 – ident: e_1_2_12_67_1 doi: 10.1002/hep.510270601 – ident: e_1_2_12_9_1 doi: 10.1038/550S101a – ident: e_1_2_12_89_1 doi: 10.1002/hep4.1079 – ident: e_1_2_12_33_1 doi: 10.1111/j.1445-5994.2012.02848.x – ident: e_1_2_12_45_1 doi: 10.1016/j.jhep.2017.09.003 – ident: e_1_2_12_86_1 doi: 10.1016/j.jhep.2017.10.015 – ident: e_1_2_12_102_1 doi: 10.1111/j.1478-3231.2008.01706.x – ident: e_1_2_12_51_1 doi: 10.1007/s00535-011-0431-9 – ident: e_1_2_12_113_1 doi: 10.1002/hep.29633 |
| SSID | ssj0011513 |
| Score | 2.5680387 |
| SecondaryResourceType | review_article |
| Snippet | Nonalcoholic fatty liver disease (NAFLD) is rapidly becoming the most common liver disease worldwide. Individuals with NAFLD have a high frequency of... |
| SourceID | proquest pubmed crossref wiley |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 328 |
| SubjectTerms | animal model awareness Disease prevention epidemiology Fatty liver Liver diseases molecular target nonalcoholic fatty liver disease (NAFLD) |
| Title | Progress and challenges in the prevention and control of nonalcoholic fatty liver disease |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fmed.21515 https://www.ncbi.nlm.nih.gov/pubmed/29846945 https://www.proquest.com/docview/2148743492 https://www.proquest.com/docview/2047257547 |
| Volume | 39 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bS-QwFA7iky-ut9XxRhQRH-zYNOkl-CReEMFlWBRcWChpLjAoHXE6D-Ov95ym7aDrgvhWmtMmTXJ6viTnfIeQA-54JpgVgZQmDYTBbIAxKwIGSi61dkWhMHb49ldyfS9uHuKHOXLaxsJ4fohuww01o_5fo4KrYnwyIw0FY9FHe4UB5uirhYDod0cdBUDHp0aGRXWQ8ChuWYXC6KR78r0t-gdgvsertcG5-kH-tk31fiaP_UlV9PXrBxbHb37LEllsgCg98zNnmczZcoUcDjyT9fSY3s0Cs8bH9JAOZhzX01XyZ4B-XfCXpKo0VLcZWcZ0WFKAlPS5YYYalV7AO8TTkaMlQv86Le9QU6eqakqf0DeENkdFa-T-6vLu_DposjQEmsc8DpzMbGYEM5ZJJ5MU8IUONUsSWShWcC6UjTIWqtBwkbrUJhk3cB9Ze0xquOI_yTxUbTcItYnKNBLIKB4LB5KOKWl04oTMVKjSHjlqxyvXDYU5ZtJ4yj35cpRDR-Z1R_bIfif67Hk7PhPabgc9b1R3DCWwhhNI2tgje10xKB2epKjSjiYggxybAHQFNGndT5aulkgCpJMCXn5UD_n_q89vLy_qi82vi26RBYBs0m8CbZP56mVidwAWVcVuPf_fAMJfCJ4 |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6VcoALlPdCAYOg6qHZxrHz8KGHim21pd1qhbZSewqOH1JFla3YrNDym_gr_U-M4ySr8pC49MAtSka2Y894PtvjbwDeMcsyTg0PhNBpwLXLBhjTIqBo5EIpWxTS3R0eHSfDE_7xND5dgR_tXRjPD9FtuDnLqOdrZ-BuQ3p7yRqK3qLvHFYbUnloFt9wwTbbORjg6L6Pov29yYdh0OQUCBSLWRxYkZlMc6oNFVYkKXpDFSqaJKKQtGCMSxNlNJShZjy1qUkypvG945jRqWaSYbm34LbLIO6Y-gefOrIqhFY-GTMu44OERXHLYxRG211Tr3u_3yDtdYRcu7j9-3DVdo6PbPnSn1dFX33_hTfyf-m9NbjXYG2y643jAayY8iFsjD1Z92KLTJZ3z2ZbZIOMlzTei0dwNnaha-gIiCw1UW3SmRk5LwmiZnLZkF9NSy_gY_7J1JLSrW7qzMPnilhZVQty4cJfSHMa9hhObuS3n8AqVm2eATGJzJTjyJEs5hYlLZVCq8RykclQpj3YbBUkVw1Lu0sWcpF7fukox4HL64HrwdtO9NJTk_xJaL3VsryZnWb4BZep3PFS9uBN9xnnFXdYJEsznaOMoxFFLM-xSU-9dna1RAJRq-BY-GatY3-vPh_tDeqH5_8u-hruDCejo_zo4PjwBdxFhCr8ntc6rFZf5-YlosCqeFUbH4HPN62vPwE0hWSp |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6VIiEuvB8LBQyCqodmG8eOEx84ILarltJqhVqpnILjh1RRZVdsVmj5S_wVfhTjOMmqPCQuPXCLkpHt2DOez_b4G4CXzLGcU8sjKU0WceOzAaa0jCgaudTalaXyd4cPj8TeCX93mp6uwffuLkzgh-g33LxlNPO1N_CZcTsr0lB0FkPvr7qIygO7_Irrtfnr_REO7qskGe8ev92L2pQCkWYpSyMnc5sbTo2l0kmRoTPUsaZCyFLRkjGubJLTWMWG8cxlVuTM4HtPMWMywxTDcq_AVS5i6fNEjD70XFWIrEIuZlzFR4IlaUdjFCc7fVMvOr_fEO1FgNx4uPFN-NH1TQhs-Txc1OVQf_uFNvI_6bxbcKNF2uRNMI3bsGarO7A5CVTdy21yvLp5Nt8mm2SyIvFe3oWPEx-4hm6AqMoQ3aWcmZOziiBmJrOW-mpaBYEQ8U-mjlR-bdPkHT7TxKm6XpJzH_xC2rOwe3ByKb99H9axavsQiBUq154hR7GUO5R0VEmjheMyV7HKBrDV6UehW452nyrkvAjs0kmBA1c0AzeAF73oLBCT_Eloo1Oyop2b5vgFF6ncs1IO4Hn_GWcVf1SkKjtdoIwnEUUkz7FJD4Jy9rUkEjGr5Fj4VqNif6--ONwdNQ-P_l30GVybjMbF-_2jg8dwHeGpDBteG7Bef1nYJwgB6_JpY3oEPl22uv4Ehk9jWA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Progress+and+challenges+in+the+prevention+and+control+of+nonalcoholic+fatty+liver+disease&rft.jtitle=Medicinal+research+reviews&rft.au=Cai%2C+Jingjing&rft.au=Zhang%2C+Xiao-Jing&rft.au=Li%2C+Hongliang&rft.date=2019-01-01&rft.issn=1098-1128&rft.eissn=1098-1128&rft.volume=39&rft.issue=1&rft.spage=328&rft_id=info:doi/10.1002%2Fmed.21515&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0198-6325&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0198-6325&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0198-6325&client=summon |